LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...

Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator GNTbm-38, with global rights for cancer ...

Scientists have experimented with bacteria as potential cancer therapy for a while now — some introduced to trigger an immune ...

A new purpose-built SACT centre in Tunbridge Wells will bring advanced cancer therapies and localised patient support to West Kent ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

Researchers have found hundreds of metabolic enzymes attached to human DNA inside the cell nucleus. Different tissues and cancers show unique patterns of these enzymes, forming a “nuclear metabolic ...

The facility will provide a full range of essential cancer treatments including chemotherapy, immunotherapy, and cellular therapy ...

Pazopanib produced responses and acceptable safety in paclitaxel-pretreated angiosarcoma; read more about outcomes and ...

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help ...

Scientists have identified a crucial molecular switch that decides whether pancreatic cancer cells resist chemotherapy or respond to it. The key player, a gene called GATA6, keeps tumours in a more ...

In this retrospective analysis, researchers studied adult patients who were diagnosed with non-metastatic breast cancer and received GLP1-RAs for at least 3 months.

A new DNA immunotherapy, Elenagen, doubled survival (13 to 25+ months) for tough ovarian cancers when added to chemotherapy, with fewer side effects.